Press Releases

Date Description View
10/31/18

Denali Therapeutics Announces Broad Collaboration With Sanofi To Develop RIPK1 Inhibitors For The Treatment Of Neurological And Inflammatory Diseases

10/03/18

CENTOGENE And Denali Therapeutics Announce Strategic Collaboration To Recruit LRRK2 Patients For Clinical Trials

08/09/18

Denali Therapeutics Reports Second Quarter 2018 Financial Results

08/07/18

Denali Therapeutics Appoints Dana Andersen, Ph.D., As Chief Technical And Manufacturing Officer

08/01/18

Denali Therapeutics Announces Positive Clinical Results From LRRK2 Inhibitor Program For Parkinson’s Disease

05/30/18

Denali Therapeutics Announces Early Exercise Of Its Option To Acquire F-Star Gamma

05/11/18

Denali Therapeutics Reports First Quarter 2018 Financial Results

03/19/18

Denali Therapeutics Announces First-In-Human Dosing Of Its RIPK1 Inhibitor Clinical Program And The Appointment Of Peter Klein To Board Of Directors; Reports Fourth Quarter And Full Year 2017 Financial Results And Business Highlights

02/08/18

Denali Therapeutics And Lonza Pharma & Biotech Announce Exclusive Partnership To Develop And Produce Biologic Medicines

01/05/18

Takeda And Denali Therapeutics Collaborate To Develop And Commercialize Therapies For Neurodegenerative Diseases

Investors & Media Relations